Business
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category
Recognized for Advancing (Z)-Endoxifen, a Precision-Engineered Endocrine Therapy with Potential Across Multiple Breast Cancer and Rare Disease
About this update from Atossa Therapeutics, Inc.
[{"type":"text","content":"Recognized for Advancing (Z)-Endoxifen, a Precision-Engineered Endocrine Therapy with Potential Across Multiple Breast Cancer and Rare Disease SettingsSEATTLE, Dec. 17, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (\"Atossa\" or the \"Company\"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, announces that it has been selected as a winner of the 2025 Clinical Trials Arena Excellence Awards. The Company was honored with the Research and Development Award in the Precision Endocrine Therapy category.\n \n \n \n \n \n \n \nAtossa earned this recognition for its innovative work advancing (Z)-endoxifen, its lead precision-engineered endocrine therapy. (Z)-endoxifen is a potent selective estrogen receptor modulator/degrader (SERM/D) with additional PKCĪ²1 inhibition, designed to provide consistent systemic exposure independent of CYP2D6 metabolism. The therapy is being evaluated across metastatic, neoadjuvant, adjuvant, and breast cancer risk-reduction settings, with an emerging application in Duchenne Muscular Dystrophy (DMD).\"This award highlights our team's commitment to precision endocrine therapy and our integrated approach to developing (Z)-endoxifen for patients with high unmet medical needs,\" said Steven Quay, M.D., Ph.D., Atossa Therapeutics' President and Chief Executive Officer. \"By combining biomarker-driven clinical studies, adaptive trial designs, and proactive regulatory engagement, we are advancing a therapy that has the potential to make a meaningful impact across multiple patient populations.\"The Clinical Trials Arena Excellence Awards recognize companies and initiatives that demonstrate scientific rigor, innovation, and leadership in clinical research and drug development. Powered by GlobalData's business intelligence and independent analysis, the program evaluates more than one billion datasets annually to identify top-performing companies and technologies shaping the future of the life sciences industry.About (Z)-Endoxifen(Z)-Endoxifen is a potent Selective Estrogen Receptor Modulator/Degrader (SERM/D) with demonstrated activity across multiple mechanisms of interest. Atossa is evaluating its potential applications in oncology and rare diseases. The Company's proprietary oral formulation has shown a favorable safety...